Published on Monday, January 16, 2017
MOUNT CLEMENS, Mich.—McLaren Macomb, through the health system-owned McLaren Cardiovascular Institute, has begun offering the only FDA-approved fully, naturally-dissolving heart stent as a treatment option for patients suffering from coronary artery disease. The first medical device of its kind, the Abbott Absorb™ bioresorbable stent has produced enhanced clinical outcomes in patients without the concern of a permanent implant.
A clogging of the arteries, restricting blood flow to the heart, coronary artery disease (CAD) affects more than 15 million Americans and remains a leading causes of death worldwide. The Absorb stent is a major advancement in the treatment of CAD.
“The approval and launch of this device represents a significant advancement in our ability to treat chronic heart disease,” said Dr. Timothy Logan, an interventional cardiologist with the McLaren Cardiovascular Institute. “Dissolved entirely after three years, patients and physicians alike don’t have to commit themselves to a permanent implant, which leads to reduced anxiety while also maintaining the standard of care.”
Traditionally, stents were permanent, metal implants. The Absorb stent is made of a naturally-dissolving material similar to dissolving sutures, disappearing after three years. After having completed its task of keeping a clogged artery open, the stent leaves behind only four markers for future reference of its placement.
During extensive clinical trials, the Absorb stent maintained the standard of care established by the leading metallic stent. However, no metal will allow the stented artery to naturally pulse and flex as the demands of the heart change with the increase and decrease of daily, physical activity.
McLaren Cardiovascular Institute interventional cardiologists underwent extensive training to ensure optimal clinical outcomes.
To learn more about the cardiac care offered at the McLaren Cardiovascular Institute or to schedule an appointment with a cardiologist, visit mclarenheart.org.
About McLaren Macomb
In January 2012, Mount Clemens Regional Medical Center became McLaren Macomb.
McLaren Macomb is a 288-bed acute care hospital located in Mount Clemens, Mich. More than 400 physicians and nearly 2,000 employees work at McLaren Macomb making it one of Macomb County’s top employers. McLaren Macomb provides a full range of services, including cancer and cardiovascular care. As Macomb County’s first verified trauma center, the hospital operates the busiest emergency department in Macomb County and is also an accredited chest pain center. McLaren Macomb has a rich history of providing high quality, compassionate health care and holds a strong position in the community it serves. To learn more, visit mclaren.org/macomb or subscribe to our blog mclaren.org/macombblog.
About McLaren Health Care
McLaren Health Care, headquartered in Flint, Michigan, is a fully integrated health network committed to quality evidence-based patient care and cost efficiency. The McLaren system includes 12 hospitals, ambulatory surgery centers, imaging centers, the state’s only proton therapy center, an employed primary care physician network, commercial and Medicaid HMOs covering more than 250,000 lives, home health and hospice providers, retail medical equipment showrooms, pharmacy services, and a wholly owned medical malpractice insurance company. McLaren operates Michigan’s largest network of cancer centers and providers, anchored by Karmanos Cancer Institute, one of only two National Cancer Institute-designated comprehensive cancer centers in the state. McLaren has 21,000 employees and more than 25,000 network providers. Its operations are housed in more than 300 facilities serving a 54-county market and 75 percent of Michigan’s population. Learn more at mclaren.org.